Nanoplatform-based cellular reactive oxygen species regulation for enhanced oncotherapy and tumor resistance alleviation

作     者：Meifang Wang Ping’an Ma Jun Lin Meifang Wang;Ping'an Ma;Jun Lin

作者机构：State Key Laboratory of Rare Earth Resource UtilizationChangchun Institute of Applied ChemistryChinese Academy of SciencesChangchun 130022China 

出 版 物：《Chinese Chemical Letters》 (中国化学快报（英文版）)

年 卷 期：2023年第34卷第9期

页      面：85-99页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 10[医学] 0702[理学-物理学] 

基　　金：financially supported by the National Key Research and Development Program of China(No.2022YFB3804500) the National Natural Science Foundation of China(NSFC,Nos.51929201 and 52102354) the projects for Science and Technology Development Plan of Jilin province(Nos.20210402046GH and 20220508089RC) 

主　　题：Nanoagents ROS regulation ROS-mediated cancer therapy Multidrug resistance Thermoresistance 

摘      要：The cancer cells realize their proliferation and metastasis activities based on the special redox adaptation to increased reactive oxygen species(ROS)level,which inversely makes them sensitive to external interference with their redox *** view of this,in recent decades,researchers have made great efforts to construct a series of novel nanoplatform-based ROS-mediated cancer therapies through increasing ROS generation and inhibiting the ROS ***,the multidrug resistance and thermoresistance of tumor are closely related to tumor redox ***,numerous works have shown that ROS regulation in cancer cells can intervene in the expression,function and stability of related proteins to achieve reversal of tumor *** this review,the recent researches about ROS-regulating nanoagents on cancer therapy and tumor resistance alleviation have been well ***,the challenges and research directions of ROS-regulating nanoagents for future clinical translation are also discussed.